Wuhan Coronavirus Could Test the Trump Administration ’s Ability to Respond to a Crisis. Experts are Worried
As a new strain of coronavirus moves from the Wuhan province of China to other parts of the world, including the United States, public health leaders are advising government officials to embrace a deliberate, measured response. But with President Donald Trump at the helm of an often unpredictable administration, infectious disease and epidemic experts tell TIME they’re concerned about which officials will have the President’s ear, and how the Commander-in-Chief will manage his Twitter presence during a potential pandemic. On Friday, Health and Human Services Secretary Alex Azar announced that, against the advice of the World Health Organization, the U.S. was declaring the coronavirus a public health emergency and denying entry to any foreign national who “poses a risk” of transmitting the virus. The WHO on Thursday had recommended against limiting trade and movement; doing so can potentially exacerbate the problem by encouraging those in impacted areas to move through underground channels and stigmatizing the sick. Experts say the coronavirus may be coming at a time when the administration is unprepared. Several high-level health officials have left the administration in the last few years and significant vacancies remain. Trump began his administration with Rear Admiral Timothy Ziemer, a long-time official who had served under President George W. Bush and Barack Obama, leading a global health security team on the White House National Security Counc...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Curious what people think with pandemic and lack of away rotations.
Publication date: 15 February 2021Source: Personality and Individual Differences, Volume 170Author(s): Brian W. Haas, Fumiko Hoeft, Kazufumi Omura
Publication date: Available online 10 October 2020Source: Academic PediatricsAuthor(s): Bonnie Crume
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
More News: Allergy | Allergy & Immunology | American Health | Centers for Disease Control and Prevention (CDC) | China Health | Coronavirus | COVID-19 | Ebola | Ebola Vaccine | Emergency Medicine | Epidemics | Epidemiology | Funding | Government | Health | Infectious Diseases | International Medicine & Public Health | Iran Health | Middle East Health | National Institutes of Health (NIH) | North Korea Health | Obama | Outbreaks | Pandemics | Science | Study | Trump | USA Health | Vaccines | Veterinary Vaccinations | WHO